{"id":"W4313729039","doi":"10.1093/bjd/ljac021","title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dermatrials Research","funders":"Cilag; LEO Pharma; Novo Nordisk; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer","keywords":"Open label; Randomized controlled trial; Plaque psoriasis; Medicine; Term (time); Psoriasis; Extension (predicate logic); Surgery; Dermatology; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008025527,0.0009981617,0.003318968,0.0003650814,0.0006974582,0.001458537,0.0009043688,0.002365371,0.004765081],"category_scores_gemma":[0.006638302,0.0006942099,0.003885454,0.0005299182,0.001173954,0.001974146,0.0007468463,0.004181607,0.000724773],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006469243,"about_ca_system_score_gemma":0.00116279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005021847,"about_ca_topic_score_gemma":0.0009271681,"domain_scores_codex":[0.9962072,0.002395067,0.0002551372,0.0004525734,0.0003974922,0.0002925378],"domain_scores_gemma":[0.9942662,0.001651446,0.001954006,0.0006577211,0.0004265888,0.001044015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9751883,0.005821005,0.00190837,0.0005672074,0.001641695,0.0000204138,0.00004872303,0.0001686763,0.0008524692,0.00008117288,0.0007438305,0.0129582],"study_design_scores_gemma":[0.8642966,0.1141674,0.01672994,0.0001404064,0.002185745,0.00005923494,0.00003508841,0.0003934184,0.0004022147,0.0002316103,0.001321168,0.00003724535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770989,0.01616214,0.0005733676,0.0009273752,0.0004357623,0.001489403,0.001057358,0.00006448726,0.002191244],"genre_scores_gemma":[0.9859177,0.004533303,0.001120763,0.001532387,0.0008388551,0.002593669,0.00159682,0.00002363464,0.001842902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008025527,"threshold_uncertainty_score":0.04244357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01857848623439885,"score_gpt":0.2485509443510118,"score_spread":0.229972458116613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}